肿瘤防治研究2023年第50卷第1期CancerResPrevTreat,2023,Vol.50,No.1·58·doi:10.3971/j.issn.1000-8578.2023.22.0695·临床研究·外周血生物标志物与免疫检查点抑制剂治疗晚期食管癌疗效的相关性王培伟，翁一鸣，崔雪，彭敏CorrelationBetweenPeripheralBloodBiomarkersandImmuneCheckpointInhibitorsinTreatmentofAdvancedEsophagealCancerWANGPeiwei,WENGYiming,CUIXue,PENGMinCancerCenter,RenminHospitalofWuhanUniversity,Wuhan430060,ChinaCorrespondingAuthor:PENGMin,E-mail:mpeng320@whu.edu.cnAbstract:ObjectiveToexploretheeffectofperipheralbloodmarkersontheefficacyandprognosisofpatientswithadvancedesophagealcancertreatedwithimmunecheckpointinhibitors(ICIs).MethodsThecasedataof61patientswithadvancedesophagealcancerwhomettheinclusioncriteriawerecollected.Dataonclinicalindicatorsandperipheralbloodmarkersaswellasobjectiveresponserate(ORR)andprogression-free-survival(PFS)wereobtained.ResultsThemedianPFSoftheincludedpatientswas7.10months(95%CI:5.12-9.07).TheORRofpatientswithbaselinelactatedehydrogenase(LDH)<201wasbetterthanthatofpatientswithLDH≥201(P<0.05).UnivariateanalysisshowedthatbaselineLDH0<201,neutrophiltolymphocyteratio(NLR)<3.9,platelet-to-lymphocyteratio(PLR)<240.3,andLDH1<249.0twoweeksafterICItreatmentweresignificantlyassociatedwithsignificantimprovementinPFS(P<0.05).Inmultivariateanalysis,patientswithNLR0<3.9hadlongerPFS(P<0.05).ConclusionLDH0<201,NLR0<3.9,PLR0<240.3,andLDH1<249.0arepositivelycorrelatedwiththeprognosisofpatientswithadvancedesophagealcancertreatedwithICIs.Keywords:Peripheralbloodbiomarkers;Esophagealcancer;Immunecheckpointinhibitors;Prediction;EfficacyCompetinginterests:Theauthorsdeclarethattheyhavenocompetinginterests.摘要：目的探讨外周血标志物对于接受免疫检查点抑制剂（ICIs）治疗的晚期食管癌患者疗效和预后的影响。方法收集61例满足纳入标准的晚期食管癌患者资料，包括临床指标、外周血标志物，观察其客观缓解率（ORR）和无进展生存期（PFS）。结果纳入患者中位PFS为7.10个月（95%CI:5.12~9.07）。基线乳酸脱氢酶（LDH）<201患者的ORR优于LDH≥201患者（P<0.05）。单因素分析显示基线LDH0<201...
